文献速递新发突发、热带与寄生虫病

卡巴喹对恶性疟原虫的因果性化学预防活性:荷兰一项随机双盲安慰剂对照控制性人类疟疾感染研究

Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
PubMed 文献 · Lancet Infect Dis · 2023-07-03

该1b期随机双盲安慰剂对照适应性剂量探索单中心研究在荷兰招募39名无疟疾免疫力健康成人,直接静脉接种恶性疟原虫子孢子后单次口服卡巴喹200、100、80、60或30 mg或安慰剂,观察28天内血症发生情况。结果显示剂量依赖性因果性化学预防效应,100 mg及以上剂量在早期或晚期肝阶段给药均提供100%保护,所有剂量安全耐受。

要点

  • 100 mg及以上单次口服卡巴喹在早期或晚期肝阶段给药均提供100%保护(3/3),至研究第28天无血症。
  • 60 mg组6例中4例(67%)、80 mg组6例中5例(83%)获得保护,30 mg组和安慰剂组全部出现血症。
  • 卡巴喹所有剂量安全耐受,最常见药物相关不良事件为头痛,多数不良事件为轻度、一过性。

核心结论

  • 卡巴喹具有剂量依赖性因果性化学预防活性,100 mg及以上单次口服在早期或晚期肝阶段给药均提供100%保护。
  • 结合既往显示的血液阶段活性和超过150 h的半衰期,结果提示卡巴喹可开发为每月一次的单剂疟疾预防方案。

研究设计与样本

  • 1b期随机双盲安慰剂对照适应性剂量探索单中心研究,在荷兰莱顿进行,招募18-45岁无疟疾免疫力健康成人。
  • 参与者分为五个队列,按3:1随机分配接受卡巴喹或安慰剂,随机化由独立统计师使用区组大小为四的置换区组方案完成。
  • 单次口服卡巴喹200、100、80、60或30 mg或匹配安慰剂,于直接静脉接种后2 h(早期肝阶段)或96 h(晚期肝阶段)给药。
  • 主要终点基于符合方案分析集:接种后28天内发生血症的参与者数、至血症时间、有记录血液阶段寄生虫生长的参与者数、疟疾临床症状及暴露-疗效建模。
  • 共39名健康参与者入组,早期肝阶段组:30 mg(n=3)、60 mg(n=6)、80 mg(n=6)、100 mg(n=3)、200 mg(n=3)、合并安慰剂(n=6);晚期肝阶段组:60 mg(n=3)、100 mg(n=3)、200 mg(n=3)、合并安慰剂(n=3)。

主要发现

  • 60 mg组6例中4例(67%)、80 mg组6例中5例(83%)、100 mg和200 mg组各3例全部至研究第28天获得保护免于血症,而合并安慰剂组和30 mg组全部出现血症。
  • 早期肝阶段疟疾中,30、60、80 mg卡巴喹组中位至血症时间分别延长至15、22、24天,合并安慰剂组为10天。
  • 除合并安慰剂组1例和30 mg卡巴喹组1例外,所有血症阳性参与者均显示有记录的血液阶段寄生虫生长。
  • 早期和晚期肝阶段组多数参与者未出现任何疟疾症状,报告的症状均为轻度。
  • 所有卡巴喹剂量安全耐受;早期肝阶段组27例中26例(96%)、晚期肝阶段组12例中10例(83.3%)报告至少一项治疗中出现的不良事件(TEAE),多数为轻度、一过性且无后遗症,最常见的卡巴喹相关TEAE为头痛,未观察到TEAE发生率、严重程度或因果关系的剂量相关趋势。

关键数值与推荐

  • 单次口服100 mg或更高剂量卡巴喹在早期或晚期肝阶段给药均提供100%保护免于血症(每组3/3)。
  • 60 mg组保护率67%(4/6),80 mg组保护率83%(5/6),30 mg组和安慰剂组保护率0%。
  • 早期肝阶段中位至血症时间:30 mg组15天、60 mg组22天、80 mg组24天,合并安慰剂组10天。
  • 卡巴喹半衰期超过150 h。

临床怎么用

  • 作者认为,结合既往显示的血液阶段活性和超过150 h的半衰期,结果提示卡巴喹可开发为每月一次的单剂疟疾预防方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabamiquine is a novel antimalarial that inhibits Plasmodium falciparum translation elongation factor 2. We investigated the causal chemoprophylactic activity and dose-exposure-response relationship of single oral doses of cabamiquine following the direct venous inoculation (DVI) of P falciparum sporozoites in malaria-naive, healthy volunteers. METHODS: This was a phase 1b, randomised, double-blind, placebo-controlled, adaptive, dose-finding, single-centre study performed in Leiden, Netherlands. Malaria-naive, healthy adults aged 18-45 years were divided into five cohorts and randomly assigned (3:1) to receive cabamiquine or placebo. Randomisation was done by an independent statistician using codes in a permuted block schedule with a block size of four. Participants, investigators, and study personnel were masked to treatment allocation. A single, oral dose regimen of cabamiquine (200, 100, 80, 60, or 30 mg) or matching placebo was administered either at 2 h (early liver-stage) or 96 h (late liver-stage) after DVI. The primary endpoints based on a per-protocol analysis set were the number of participants who developed parasitaemia within 28 days of DVI, time to parasitaemia, number of participants with documented parasite blood-stage growth, clinical symptoms of malaria, and exposure-efficacy modelling. The impact of cabamiquine on liver stages was evaluated indirectly by the appearance of parasitaemia in the blood. The Clopper-Pearson CI (nominal 95%) was used to express the protection rate. The secondary outcomes were safety and tolerability, assessed in those who had received DVI and were administered one dose of the study intervention. The trial was prospectively registered on ClinicalTrials.gov (NCT04250363). FINDINGS: Between Feb 17, 2020 and April 29, 2021, 39 healthy participants were enrolled (early liver-stage: 30 mg [n=3], 60 mg [n=6], 80 mg [n=6], 100 mg [n=3], 200 mg [n=3], pooled placebo [n=6]; late liver-stage: 60 mg [n=3], 100 mg [n=3], 200 mg [n=3], pooled placebo [n=3]). A dose-dependent causal chemoprophylactic effect was observed, with four (67%) of six participants in the 60 mg, five (83%) of six participants in the 80 mg, and all three participants in the 100 and 200 mg cabamiquine dose groups protected from parasitaemia up to study day 28, whereas all participants in the pooled placebo and 30 mg cabamiquine dose group developed parasitaemia. A single, oral dose of 100 mg cabamiquine or higher provided 100% protection against parasitaemia when administered during early or late liver-stage malaria. The median time to parasitaemia in those with early liver-stage malaria was prolonged to 15, 22, and 24 days for the 30, 60, and 80 mg dose of cabamiquine, respectively, compared with 10 days for the pooled placebo. All participants with positive parasitaemia showed documented blood-stage parasite growth, apart from one participant in the pooled placebo group and one participant in the 30 mg cabamiquine group. Most participants did not exhibit any malaria symptoms in both the early and late liver-stage groups, and those reported were mild in severity. A positive dose-exposure-efficacy relationship was established across exposure metrics. The median maximum concentration time was 1-6 h, with a secondary peak observed between 6 h and 12 h in all cabamiquine dose groups (early liver-stage). All cabamiquine doses were safe and well tolerated. Overall, 26 (96%) of 27 participants in the early liver-stage group and ten (83·3%) of 12 participants in the late liver-stage group reported at least one treatment-emergent adverse event (TEAE) with cabamiquine or placebo. Most TEAEs were of mild severity, transient, and resolved without sequelae. The most frequently reported cabamiquine-related TEAE was headache. No dose-related trends were observed in the incidence, severity, or causality of TEAEs. INTERPRETATION: The results from this study show that cabamiquine has a dose-dependent causal chemoprophylactic activity. Together with previously demonstrated activity against the blood stages combined with a half-life of more than 150 h, these results indicate that cabamiquine could be developed as a single-dose monthly regimen for malaria prevention. FUNDING: The healthcare business of Merck KGaA, Darmstadt, Germany.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. van der Plas JL, Kuiper VP, Bagchus WM, et al. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023. PMID: 37414066. doi:10.1016/S1473-3099(23)00212-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。